Gilead Sciences (NASDAQ:GILD) submits
NDA for filgotinib, an investigational, oral, selective JAK1 inhibitor
for the treatment of adults with rheumatoid arthritis (RA) to the
Japanese Ministry of Health, Labor and Welfare.
Filgotinib is an investigational agent and is not
approved anywhere globally. Its efficacy and safety have not been
established by any regulatory authorities.
https://seekingalpha.com/news/3504383-gilead-sciences-submits-nda-filgotinib-japan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.